Clinical Report: Evaluation of Abortion Care Attributes and Telehealth Access

Overview

This study evaluates the attributes of abortion care and access to telehealth for patients undergoing medication abortion, highlighting the shift towards telehealth models in response to policy changes.

Background

The approval of mifepristone in 2000 marked a significant advancement in medication abortion. Recent policy changes, particularly during the COVID-19 pandemic and following the Dobbs v. Jackson Women’s Health Organization ruling, have facilitated the expansion of telehealth for medication abortion. Understanding patient preferences in abortion care is crucial for tailoring healthcare approaches.

Data Highlights

No numerical data or trial data was provided in the source material.

Key Findings

• Medication abortion now accounts for the majority of abortions in the United States.
• Telehealth accounts for 1 in 4 abortions nationally.
• Patients have expressed preferences for medication abortion over procedural abortion and telehealth over in-person care.
• Telehealth models may improve access to abortion care, particularly for those in rural areas or states with abortion bans.
• Privacy and convenience are significant factors influencing patient preferences for telehealth abortion care.

Clinical Implications

Healthcare providers should consider the varying preferences of patients regarding telehealth and in-person abortion care. Tailoring approaches to meet these preferences may enhance patient satisfaction and access to care.

Conclusion

Understanding patient preferences in abortion care is essential as telehealth continues to evolve as an option for medication abortion.

Related Resources & Content

1. Stat News, 2026 -- Telehealth abortion with mifepristone continues, with backup plans still in place
2. Drug Safety, 2025 -- Insights from Real-World Data on Antidepressant Use and Adherence Among Pregnant Women in Catalonia, Spain
3. Frontiers in Reproductive Health, 2026 -- Abortion knowledge, attitudes and reproductive autonomy among university students in Austria: a cross-sectional study
4. JAMA Network Open, 2023 -- Abortion Bans and Pregnancy-Related Care Across Physician Specialties: A Qualitative Study
5. FDA -- Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation
6. Cochrane Review on Telemedicine for Medical Abortion
7. Society of Family Planning: Telemedicine in Family Planning Care
8. Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation | FDA
9. 23-235 FDA v. Alliance for Hippocratic Medicine (06/13/2024)
10. SERVICE DELIVERY Recommendation 48 (NEW) Telemedicine approaches to delivering medical abortion care - Abortion care guideline, second edition - NCBI Bookshelf
11. Comparison of No-Test Telehealth and In-Person Medication Abortion - PMC
12. Society of Family Planning Clinical Recommendation: Management of undesired pregnancy of unknown location and abortion at less than 42 days of gestation - ScienceDirect
13. Society of Family Planning: #WeCount report, April 2022 to December 2024
14. Provision of Abortion Medications Using Online Asynchronous Telemedicine Under Shield Laws in the US | Health Policy | JAMA | JAMA Network